Cargando…

The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial

INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Haiming, Wu, Feng, Fan, Zhenyu, Cheng, Xin, Cheng, Jilin, Fan, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier España, S.L.U. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287454/
https://www.ncbi.nlm.nih.gov/pubmed/32747012
http://dx.doi.org/10.1016/j.medcli.2020.06.007
_version_ 1783545066242965504
author Cui, Haiming
Wu, Feng
Fan, Zhenyu
Cheng, Xin
Cheng, Jilin
Fan, Min
author_facet Cui, Haiming
Wu, Feng
Fan, Zhenyu
Cheng, Xin
Cheng, Jilin
Fan, Min
author_sort Cui, Haiming
collection PubMed
description INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension. PATIENTS AND METHOD: In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI. RESULTS: Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated. CONCLUSIONS: Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms.
format Online
Article
Text
id pubmed-7287454
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-72874542020-06-11 The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial Cui, Haiming Wu, Feng Fan, Zhenyu Cheng, Xin Cheng, Jilin Fan, Min Med Clin (Barc) Brief Report INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension. PATIENTS AND METHOD: In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI. RESULTS: Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated. CONCLUSIONS: Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms. The Authors. Published by Elsevier España, S.L.U. 2020-10-09 2020-06-11 /pmc/articles/PMC7287454/ /pubmed/32747012 http://dx.doi.org/10.1016/j.medcli.2020.06.007 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Report
Cui, Haiming
Wu, Feng
Fan, Zhenyu
Cheng, Xin
Cheng, Jilin
Fan, Min
The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
title The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
title_full The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
title_fullStr The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
title_full_unstemmed The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
title_short The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
title_sort effects of renin–angiotensin system inhibitors (rasi) in coronavirus disease (covid-19) with hypertension: a retrospective, single-center trial
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287454/
https://www.ncbi.nlm.nih.gov/pubmed/32747012
http://dx.doi.org/10.1016/j.medcli.2020.06.007
work_keys_str_mv AT cuihaiming theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT wufeng theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT fanzhenyu theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT chengxin theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT chengjilin theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT fanmin theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT cuihaiming effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT wufeng effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT fanzhenyu effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT chengxin effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT chengjilin effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial
AT fanmin effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial